Press release
NewSelf Achieves FDA Approval for Breakthrough Weight-Loss Program, Ushering in a New Era of Affordable, Accessible Health Transformation
New York, NY - September 2, 2025 - NewSelf, a leading AI-driven health optimization platform, today proudly announced that it has received U.S. Food and Drug Administration (FDA) approval for its innovative medical weight-loss treatment program. The approval confirms NewSelf's commitment to delivering safe, science-backed therapies to individuals across the nation seeking a sustainable solution to weight management, metabolic health, and long-term wellness.This milestone is a validation of years of innovation, rigorous medical oversight, and a mission rooted in making cutting-edge health tools not only effective-but also affordable and accessible to everyone.
FDA Approval: A Turning Point in Weight-Loss Care
The obesity epidemic remains one of the most pressing health crises of the modern era, with nearly 42% of American adults classified as obese according to the CDC. Despite the widespread prevalence, access to advanced pharmaceutical treatments has remained limited due to high costs, insurance restrictions, and confusing medical pathways.
With FDA approval of NewSelf's medical weight-loss program, patients now have direct access to FDA-approved medications based on semaglutide and tirzepatide, the same active ingredients in Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. These GLP-1 receptor agonists have been clinically proven to produce transformative weight loss results while improving metabolic markers such as blood sugar, cholesterol, and blood pressure.
Unlike traditional clinics or pharmacies, NewSelf integrates FDA-approved treatments into a comprehensive, end-to-end telehealth experience:
Virtual Medical Consultations: Patients complete a streamlined intake and are matched with a licensed clinician for approval and dosage determination.
Fast, Affordable Delivery: Once prescribed, medication is shipped discreetly-often overnight-at prices up to 40% lower than competitors, with no hidden fees or dosage-based upcharges.
Ongoing Support: Patients receive monthly follow-ups, educational resources, and AI-powered health guidance directly within the NewSelf platform.
This combination of FDA approval, affordability, and intelligent technology support makes NewSelf a first-of-its-kind provider in the U.S. weight-loss market.
Leadership Perspective
"FDA approval is more than a regulatory milestone-it's proof that innovation, safety, and accessibility can co-exist in modern medicine," said John Edwards, CEO of NewSelf. "We believe everyone deserves access to effective weight-loss treatments without financial or logistical barriers. This approval empowers us to deliver real, lasting results to millions of Americans who have struggled under the weight of an outdated healthcare system."
Dr. Boyer, Chief Medical Officer of NewSelf, added: "Our patients will benefit from the gold standard of weight-loss care-FDA-approved therapies combined with personalized oversight. But what truly sets NewSelf apart is our integration of advanced AI tools to help patients track progress, stay accountable, and maintain long-term results."
Clinical Evidence and Patient Outcomes
Semaglutide and tirzepatide have been studied extensively, with clinical trials showing average weight reduction of 15-20% of body mass within 12-18 months. Patients also report improvements in energy levels, sleep, and mental well-being.
By embedding these treatments within a broader wellness ecosystem, NewSelf is addressing not only the medical side of weight loss, but also the psychological and lifestyle challenges that accompany it. The platform's AI-enabled support system provides personalized reminders, health tips, and behavior-tracking, allowing patients to sustain progress well beyond the initial phase of treatment.
"Weight loss is not just about medication-it's about creating a system of support, accountability, and science-backed coaching," explained Dr. Boyer. "That's why we've combined the best of medicine with the best of technology."
Affordability and Accessibility
One of the most significant barriers to medical weight-loss care has been cost. Some patients face monthly bills of $1,000 or more through traditional providers, creating a divide between those who can access treatments and those left behind.
NewSelf's FDA-approved program shatters that barrier. Through strategic partnerships with licensed compounding pharmacies and an optimized telehealth model, NewSelf offers treatments at a fraction of the cost, with flat-rate pricing regardless of dosage escalation. Patients pay for outcomes, not arbitrary dosage tiers-a transparency rarely seen in the healthcare industry.
Additionally, the program is available nationwide, reaching patients in all 50 states. This eliminates geographic inequities that have historically limited access to cutting-edge care.
The Future of Healthcare: AI Meets Medicine
While FDA approval validates NewSelf's medical program, the company's broader mission is to redefine what it means to "own your health."
Through its mobile app and digital ecosystem, NewSelf combines FDA-approved treatments with AI-driven health optimization tools, including:
Daily Health Tracking - Nutrition, exercise, sleep, and medication adherence.
AI-Powered Recommendations - Personalized adjustments based on user progress and goals.
Community & Coaching - Support groups, expert Q&As, and access to certified health coaches.
Future Expansion - Beyond weight loss, NewSelf plans to expand into longevity, brain health, and metabolic optimization.
By merging telehealth, AI, and regulatory approval, NewSelf is positioning itself as the healthcare platform of the future.
Patient Testimonials
"For years, I felt trapped in a cycle of diets that never worked. With NewSelf, I finally found something that wasn't just a promise, but a proven solution. The medication worked, but what really changed my life was the constant support and accountability I received. For the first time, I feel like my health is in my control." - Sarah M., NewSelf Patient
"Other clinics quoted me nearly double the price. NewSelf made it affordable without compromising on quality or safety. The fact that it's FDA-approved gives me peace of mind that I'm doing the right thing for my body." - David P., NewSelf Patient
NewSelf Limited
521 5th Avenue, 17th Floor
New York, NY 1017
NewSelf is an AI-enabled health optimization platform dedicated to empowering individuals to become the best version of themselves. With offerings spanning medical weight loss, daily health optimization, and future programs in longevity and brain health, NewSelf combines scientific rigor with affordability and accessibility. By integrating FDA-approved medications with AI technology, telehealth, and personalized coaching, NewSelf is redefining what's possible in modern healthcare.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release NewSelf Achieves FDA Approval for Breakthrough Weight-Loss Program, Ushering in a New Era of Affordable, Accessible Health Transformation here
News-ID: 4167023 • Views: …
More Releases for FDA
DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes…
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming
CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility…
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug…
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30).
Announcing New Design Control Training Courses
Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a…
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation.
GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet…
FDA online training
Description:
Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding…
